NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CarMax, Inc. ("CarMax, Inc." or the "Company") (NYSE: KMX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CarMax, Inc. investors who were adversely affected by alleged securities fraud between June 20, 2025 and November 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/carmax-inc-lawsuit-submission ...

NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Primo Brands Corporation / Primo Water Corporation ("Primo Brands Corporation / Primo Water Corporation" or the "Company") (NYSE: PRMB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Primo Brands Corporation / Primo Water Corporation investors who were adversely affected by alleged securities fraud between June 17, 2024 and November 6, 2025. Follow the link below to ge ...

NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CONTACT: INSP investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-717 ...

Core Viewpoint - ADC Therapeutics is under investigation for potential securities fraud and unlawful business practices following a press release regarding clinical trial data that may have misrepresented adverse events [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics, focusing on whether the company and its officers engaged in securities fraud [1]. - The investigation is prompted by concerns over the company's recent disclosures and the implications for investors [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [2]. - The press release, while positive, noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [2]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial data, ADC's stock price fell by $0.65 per share, representing a 14.13% decline, closing at $3.95 per share on December 3, 2025 [3].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors regarding operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [2][3]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, causing a bottleneck in revenue generation [3]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [3]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [3]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the January 5, 2026, Lead Plaintiff Deadline to discuss their legal rights [2][4]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities or sold put options of Sprouts Farmers Market, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Sprouts Farmers Market securities or sold put options between June 4, 2025, and October 29, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 26, 2026 [3]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that defendants provided misleading information regarding Sprouts Farmers Market's growth potential for fiscal year 2025, claiming resilience in customer base despite macroeconomic pressures [5]. - It is claimed that while positive statements were made, material adverse facts about the company's growth potential were concealed, leading to significant sales growth slowdown when the truth was revealed [5].

Group 1 - The Law Offices of Frank R. Cruz announced that investors who suffered losses related to F5, Inc. have the opportunity to lead a securities fraud class action lawsuit [1] - The lawsuit alleges that between October 28, 2024, and October 27, 2025, F5 failed to disclose a significant security incident that jeopardized its clientele's security and the company's future prospects [2] - The complaint claims that the positive statements made by F5 regarding its business, operations, and prospects were materially misleading and lacked a reasonable basis during the relevant time [2] Group 2 - Investors interested in participating in the lawsuit must act before February 17, 2026, which is the lead plaintiff deadline [2] - The Law Offices of Frank R. Cruz provides contact information for investors seeking to learn more about the lawsuit or their rights [3][5] - Potential class members do not need to take any action immediately and may choose to retain counsel or remain absent from the class action [4]

Core Viewpoint - Investors in Klarna Group plc have the opportunity to lead a securities fraud class action lawsuit due to alleged misstatements and omissions related to the company's initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Klarna's defendants materially understated the risk of increased loss reserves shortly after the September 2025 IPO, which they either knew or should have known [2]. - It is alleged that the positive statements made by the defendants regarding Klarna's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Participation Information - Investors who suffered losses related to Klarna are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for February 20, 2026 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, nimacimab, which was claimed to be less effective than represented [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [3]. - Allegations include that the defendants made materially false and misleading statements about nimacimab's effectiveness and its clinical, regulatory, and commercial prospects [3]. - The deadline for shareholders to register for the class action is January 16, 2026, and there is no cost to participate [4]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to deceit and misleading practices by companies [5]. - The firm emphasizes the importance of responsible business practices and good corporate citizenship [5].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Maryland, titled Jason Cap v. CarMax, Inc., et al., No. 1:25-cv-03602, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 2, 2026, to request to be appointed to lead the case [3]. Group 2: Reasons for the Lawsuit - CarMax is accused of misleading investors by promoting strong demand for its used cars, which was allegedly inflated by a temporary boost in sales due to U.S. tariffs on cars [4]. - The unexpected departure of CEO Bill Nash on November 6, 2025, is also under investigation to determine if CarMax properly assessed its portfolio of car loans [5]. Group 3: Stock Performance - On September 25, 2025, CarMax reported disappointing financial results, including a 5.4% decline in retail used unit sales and a net income drop from $132.8 million to approximately $95.4 million year-over-year [6]. - Following the financial report, CarMax's stock price fell by $11.45 per share, or about 20%, from $57.05 to $45.60 [7]. - The announcement of CEO Bill Nash's departure and a weak preliminary Q3 2025 outlook led to an additional stock drop of over 24% [7].